Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × Quercetin × Clear all

NCT06355037 2024-07-08

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms